Logo

Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate) in P-III QUARTZ Study for Inadequately Controlled Asthma

Share this

Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate) in P-III QUARTZ Study for Inadequately Controlled Asthma

Shots:

  • The P-III QUARTZ study results involves assessing of QMF149 (150/80 Mu g) vs mometasone furoate (200 Mu g) delivered via Breezhaler & Twisthaler in 802 adult and adolescent patients in a ratio (1:1) with inadequately controlled asthma respectively
  • The P-III QUARTZ study results: @12wks. met its 1EPs & 2EPs; improvement in lung function; improvements in evening PEF (26.1 L/min); improvements in asthma control as measured by ACQ-7 (74.7% vs 64.9%); AEs (32.3% vs 38.3%)
  • QMF149 (qd) is an inhaled fixed-dose combination therapy delivered with the dose-confirming Breezhaler device and is evaluated under Novartis’ P-III PLATINUM Program. Novartis enters into an exclusive license agreement with Merck for mometasone furoate to use in QMF149 candidate

Ref: Novartis | Image: Pinterest

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions